ElevateBio Appoints Larry Lockwood, Ph.D., As Chief Commercial Officer To Lead Commercial Strategy And Growth

ElevateBio, a technology-driven company dedicated to advancing the development of life-transforming genetic medicines, has announced the appointment of Larry Lockwood, Ph.D., as its Chief Commercial Officer. Dr. Lockwood brings more than two decades of leadership experience and technical expertise, with a strong track record in building and scaling commercial teams, driving revenue growth, and forging global partnerships. 

In his new role, he will be responsible for leading the company’s commercial strategy to accelerate growth, expand partnerships at BaseCamp, ElevateBio’s cGMP manufacturing business and monetize the cutting-edge technologies and platforms of Life Edit, its gene editing and R&D technology division. His ability to transform advanced manufacturing solutions and technologies into substantial commercial contracts is expected to play a pivotal role in strengthening ElevateBio’s market share in the rapidly growing field of genetic medicine.

Ger Brophy, Chief Executive Officer of ElevateBio, stated, "Larry is joining ElevateBio at a key moment along our growth trajectory, as BaseCamp is expanding its capabilities and impact while Life Edit continues to make immense advancements to its gene editing platform. His proven ability to drive significant revenue growth for global contract development manufacturing organizations (CDMOs), combined with his extensive experience supporting customers across North America, Europe and Asia, makes him the ideal leader to commercialize our integrated technology and manufacturing offerings and ultimately deliver on our vision to change the future of genetic medicine.”

Larry Lockwood, Ph.D., mentioned, “The genetic medicines market demands both cutting-edge technologies and scalable manufacturing reliability – a combination few can deliver. This is an exciting opportunity to tap into the unique integrated approach that ElevateBio has built to offer biopharmaceutical partners end-to-end solutions to successfully bring their innovative therapies to patients. By demonstrating ElevateBio’s value from early-stage discovery through commercial-scale manufacturing, we can create a new paradigm for genetic medicine development while building a robust commercial foundation for our future.”

Before joining ElevateBio, Dr. Lockwood held several leadership positions at Aldevron, a part of Danaher Life Sciences, where he most recently served as Global Head of CDMO Strategy. In that role, he spearheaded go-to-market strategy development and established strategic partnerships with contract development and manufacturing organizations (CDMOs) worldwide, significantly enhancing the client experience. 

Earlier at Aldevron, he served as Vice President of Key Accounts and Vice President of Sales, where he was instrumental in driving commercial success. His previous experience also includes business development and sales leadership roles at RoosterBio Inc., Horizon Discovery Ltd., Lonza Biologics, Inc., and AMRI Inc. Dr. Lockwood holds a Ph.D. in Organic Chemistry from Rensselaer Polytechnic Institute and a B.S. in Chemistry from Towson State University.